Mini‐hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B‐acute lymphoblastic leukemia
Author:
Affiliation:
1. Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas USA
2. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Publisher
Wiley
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29939
Reference22 articles.
1. Childhood Leukemias
2. Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
3. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
4. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post‐reinduction therapy in high and intermediate risk (HR/IR) first relapse of B‐acute lymphoblastic leukemia (B‐ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children's Oncology Group Study AALL1331;Brown PA;Blood,2019
5. Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059;Clinical Pharmacokinetics;2024-06-22
2. Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia;Haematologica;2024-05-10
3. Multiple drugs;Reactions Weekly;2023-04-29
4. Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies;Translational Pediatrics;2023-03
5. Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation?;Journal of Hematology;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3